A phase III trial of remetinostat for the treatment of early-stage cutaneous T-cell lymphoma
Latest Information Update: 11 May 2020
At a glance
- Drugs Remetinostat (Primary)
- Indications Cutaneous T-cell lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Medivir AB
- 05 May 2020 According to a Medivir AB media release, the company has determined the design of a phase III study and is searching a partner for the continued development and commercialization of remetinostat.
- 14 Feb 2019 According to a Medivir AB media release, after having clarifying and positive discussions with the FDA regarding the design of the phase III, company is now further developing the phase III design based on the clarifications from the FDA.
- 18 Jun 2018 According to a Medivir AB media release, the company decided to continue the discussions with the US Food and Drug Administration (FDA) to agree on the design and start of the study will not be possible earlier than 2019.